Navigation Links
Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
Date:1/30/2008

the US$35.2 billion market for statin drugs globally.

"In particular there is an unmet need for a more effective treatment for elevated triglycerides and APA-01 has demonstrated efficacy in this area in this preclinical study. We are now assessing the impact of these results before determining our future strategy. However, the insulin, oxycodone and Phospha E(R) clinical programs will remain our priority for this year," Dr. Ogru said.

About Atherosclerosis

Atherosclerosis, or the build-up of fatty deposits (plaques) on interior blood vessel walls, is a progressive process initially involving endothelial dysfunction and accumulation of lipids on the linings of blood vessel. Atherosclerotic lesions develop as a result of inflammatory stimuli, subsequent release of various cytokines, proliferation of smooth muscle cells, synthesis of connective tissue matrix, and accumulation of macrophages and lipids. Atherosclerosis is involved in the development of coronary heart disease, myocardial infarction, and stroke, among other diseases.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.

Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR -- Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)...  David Hardison, Ph.D., vice president of health ... been elected chairman of the board for the ... to establish common protocols around the use of ... electronic health records. Hardison will ... organizations across the research and health care arena ...
(Date:7/28/2014)... 28, 2014 Immunomic Therapeutics, Inc. (ITI) ... further develop potential treatments for glioblastoma multiforme (GBM), the ... with their patented vaccine platform, LAMP-vax. , The ... based on the work of John H. Sampson, MD, ... Preston Robert Tisch Brain Tumor Center at Duke University ...
Breaking Biology Technology:JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4
... 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. ... contract research organization (CRO) that provides design, development, ... registries to many of the world,s leading pharmaceutical ... for the Second Annual Vaccine Industry Excellence Award ...
... service revenue of $264.5 million grows 7.8% year-over-year- ... of $0.25- Net quarterly book-to-bill ratio equates to ... PRXL ) today announced its financial ... 2009.For the three months ended March 31, 2009, ...
... Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC ... has secured rights to seven key patents from Company ... patents that will significantly enhance Sinobiopharma,s ability to execute ... to market.The patents are for the following:, ...
Cached Biology Technology:Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:7/28/2014)... fertility problems, many of these due to genetic factors. ... such genes, which reduce an individual,s ability to reproduce, ... Institute of Science that recently appeared in Nature ... only can it explain the high rates of male ... the causes of genetic diseases and their treatment. ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
Breaking Biology News(10 mins):Mutations from Venus, mutations from Mars 2Dinosaurs fell victim to perfect storm of events, study shows 2New drug target can break down cancer's barrier against treatment 2
... Might those bacteria lead oil companies to change their methods ... same time reducing the carbon dioxide that burning oil and ... be possible. Larter, professor of geoscience and holder ... University of Calgary, was the keynote speaker today for the ...
... a firm link between environmental change and human disease ... a team of scientists from the University of Wisconsin-Madison, ... of the CDC journal Emerging Infectious Diseases, ... incidence of malaria to land-use practices in the Amazon. ...
... bacteria in seven species of sharks and redfish captured ... of these wild, free-swimming fish harbored several drug-resistant bacterial ... Journal of Zoo and Wildlife Medicine , found antibiotic-resistant ... also found multidrug-resistant bacteria in fish at nearly all ...
Cached Biology News:Incidence of malaria jumps when Amazon forests are cut 2Incidence of malaria jumps when Amazon forests are cut 3Wild sharks, redfish harbor antibiotic-resistant bacteria 2
... Fermentation System to achieve high ... and maximum information output 4 ... precision with small-scale requirements provides users ... with E.coli, Pichia pastoris, yeast, fungi ...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Antibody Binding: High, 400 ng IgG/cm ... , Binding Interaction: Hydrophobic/Ionic , Performance Certified: ... Flat , Maximum Well Volume: 360 µl ... ,Features, Special optically clear polystyrene ...
...
Biology Products: